Schering Plough - Topic profile

HERE IS SOME POISTIVE NEWS FOR A CHANGE ABOUT SCHERING-PLOUGH... Replenishing The Pipeline: And The Winner Is… Company 2007 2012 Percent Change Schering-Plough 0.38 1.58 315.8% Amgen 4.50 1.46 -67.6% Bristol-Myers Squibb 1.08 0.84 -21.7% Wyeth 0.60 0.49 -18.2% Abbott Labs 1.73 0.42 -75.7% Johnson & Johnson 0.39 0.38 -2.4% GlaxoSmithKline 0.27 0.32 17.3% ...

Schering-Plough Corp., a major maker of prescription drugs and consumer health products, spent $530,000 in the second quarter to lobby on federal More...

The next chapter of the Zetia/Vytorin chapter will be released to the public on Tuesday morning, when SEAS is reported publicly at ESC. Sir Richard will be onhand to save his SHARP study. Big Rob may be there to stand up for IMPROVE-IT. Bottom line is that it won't help much. Schering-plough will be lucky if they can avoid the same fiasco in Europe as they did in the US. Given the lack of ...

You guys made your bed now cry in it. lol lol lol lol lol. Poor pu$$ies. Don't worry McCain will save you........lol lol lol lol. Where only the employees more pathetic than the drugs they make.............................................. ......................... LOSERS LOSERS LOSERS.....LOL LOL LOL yOU FOLKS BETTER LEARN HOW TO DRIVE A NAIL OR RUN A LAWN MOWER. ...

We have added new boards for: BMS IT BiogenIdec IT Elan Endo IT Jazz Pharmaceuticals IT Medimmune IT Quest Diagnostics IT SGP IT Watson IT Please follow this link for the IT boards category: http://www.cafepharma.com/boards/forumdisplay.php? f=429

Zetia Zetia (Ezetimibe) is used for treating high blood cholesterol along with a low-fat, low-cholesterol diet.[b] Drug Uses Zetia treats high blood cholesterol along with a low-fat, low-cholesterol diet. It is also used to treat high blood sitosterol and campesterol along with diet therapy >>> Buy zetia online Cheap online zetia Zetia for cheap Zetia discount online pharmacy...

I think he was in charge of the Integrelin franchise.

Schering-Plough said regulators had rejected Bridion, its drug to reverse the effects of anesthesia that had been heralded as a breakthrough product by analysts. More...

Schering-Plough said regulators had rejected Bridion, its drug to reverse the effects of anesthesia that had been heralded as a breakthrough product by analysts. More...

  Recs: 0 Arthritis Drugs Ordered to Carry Stronger Warnings - A plus for Pomalidomide???? Arthritis Drugs Ordered to Carry Stronger Warnings (Update1) By Catherine Larkin Sept. 4 (Bloomberg) -- Arthritis and autoimmune drugs marketed by Amgen Inc., Wyeth and Johnson & Johnson must carry stronger warnings about fungal infections tied to more than 45 deaths, U.S. ...

Published at www.nejm.org September 2, 2008 (10.1056/NEJMsa0806603) http://content.nejm.org/cgi/content/full/NEJMsa080 6603?query=TOC Analyses of Cancer Data from Three Ezetimibe Trials Richard Peto, F.R.S., Jonathan Emberson, Ph.D., Martin Landray, Ph.D., Colin Baigent, B.M., B.Ch., Rory Collins, M.B., B.S., Robert Clare, M.S., and Robert Califf, M.D. Editorial by Drazen,...

China's Hepatitis B Market to Double by 2012 by: ChinaBio Today posted on: September 01, 2008 | about stocks: BMY / GSK / RHHBY.PK / SGP The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of ...

Market Update 080902 http://biz.yahoo.com/mu/update.html 4:15 pm : Tuesday was a disappointing session for stock market bulls. Stocks ran out of steam, giving up strong opening gains to finish the day with a loss. Shortly after the opening bell, the Dow, Nasdaq and S&P 500 rallied 2.1%, 1.9% and 1.6%, respectively, benefiting from a sharp sell-off in commodities and a relief trade...

From Briefing.com: 4:06PM MEMC Elec reaffirms Q3 revs guidance in-line with consensus; co cites continued degree of caution in outlook (WFR) 47.10 -1.99 : Co reaffirms Q3 revs of $560-620 mln vs $596.7 mln consensus. Co also reaffirmed gross margins of 54-55% and raised operating expenses to ~$43 mln, up from the prior target of ~$41 mln, primarily due to one-time, non-cash severance ...

Stock Market Update 16:15 ET Dow -26.63 at 11516.92, Nasdaq -18.28 at 2349.24, S&P -5.25 at 1277.58 [BRIEFING.COM] Tuesday was a disappointing session for stock market bulls. Stocks ran out of steam, giving up strong opening gains to finish the day with a loss. Shortly after the opening bell, the Dow, Nasdaq and S&P 500 rallied 2.1%, 1.9% and 1.6%, respectively, benefiting ...

You read it first on CafePharma! Good call!!